BD-1047盐酸盐
BD-1047盐酸盐 性质
| 储存条件 | Inert atmosphere,2-8°C |
|---|---|
| 溶解度 | 在水中的溶解度>5mg/mL |
| 形态 | 粉末 |
| 颜色 | 白色 |
| 水溶解性 | H2O: >5mg/mL |
| 稳定性 | 自购买之日起，稳定期为 1 年。 其DMSO 或蒸馏水中的溶液可在 -20°C 下保存长达 3 个月。 |
| InChI | 1S/C13H20Cl2N2.2BrH/c1-16(2)8-9-17(3)7-6-11-4-5-12(14)13(15)10-11;;/h4-5,10H,6-9H2,1-3H3;2*1H |
| InChIKey | WOALTFHGLDVJHK-UHFFFAOYSA-N |
| SMILES | Br.Br.CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1 |
BD-1047盐酸盐 用途与合成方法
| Target | Value |
|
σ1 receptor
() |
BD-1047 (dihydrobromide) prevents that Cutamesine reduces the cell death rate induced by light exposure in murine photoreceptor-derived 661w cells.
BD-1047 (dihydrobromide) attenuates that Cutamesine reduces the mitochondrial damage and the elevated level of caspase 3/7 activity.
BD-1047 (dihydrobromide) (1-10 mg/kg; i.p.) decreases the Apomorphine (APO)-induced climbing behavior at the dose of 10 mg/kg in mice.
BD-1047 (dihydrobromide) counteracts the antidepressant-like effect induced by co-administration of pramipexole and sertraline (but not pramipexole and fluoxetine).
BD-1047 (dihydrobromide) reduces the increasing expression of pNR1, and reverses the Sig-1 R agonists potentiated NMDA-induced pain behaviour and pNR1 immunoreactivity.
| Animal Model: | Male Albino Swiss mice (50 days old, 25–28 g) |
| Dosage: | 1 mg/kg, 3 mg/kg, 10 mg/kg |
| Administration: | Intraperitoneal injection |
| Result: | Decreased the APO-induced climbing at the dose of 10 mg/kg in mice. |
安全信息
| 危险品标志 | Xi |
|---|---|
| 危险类别码 | 37/38-41 |
| 安全说明 | 26-36/37 |
| WGK Germany | 3 |
| 存储类别 | 11 - 可燃固体 |
| 危险性类别 | 严重眼损伤 类别1 经皮刺激 类别2 特异性靶器官毒性-一次接触，类别3 |
BD-1047盐酸盐 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-07-06 | S0106 | BD-1047盐酸盐 | 138356-21-5 | 5mg | 753.46 |
| 2026-07-06 | S0106 | BD-1047盐酸盐 | 138356-21-5 | 25mg | 2024.47 |
